Related Experiment Videos
Transplantation tolerance induced by CTLA4-Ig
T C Pearson1, D Z Alexander, K J Winn
1Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322.
Transplantation
|June 27, 1994
Summary
The fusion protein CTLA4-Ig can induce long-term survival and donor-specific tolerance in transplanted cardiac allografts. This immune suppression therapy shows promise for preventing organ transplant rejection.
Area of Science:
- Immunology
- Transplantation Biology
- Drug Development
Background:
- Allograft rejection is mediated by T cell activation, requiring antigen recognition and costimulatory signals.
- CD28 is a key T cell surface molecule involved in costimulation.
- CTLA4-Ig is a fusion protein that inhibits CD28-mediated costimulation.
Purpose of the Study:
- To investigate the efficacy of CTLA4-Ig in inducing transplantation tolerance in a murine cardiac allograft model.
- To assess the long-term graft survival and donor-specific tolerance following CTLA4-Ig treatment.
Main Methods:
- BALB/c cardiac allografts were transplanted into C3H/He recipients.
- Recipients received a 12-day course of CTLA4-Ig treatment.
- Graft survival was monitored, and donor-specific tolerance was assessed using skin grafts.
Main Results:
- CTLA4-Ig treatment resulted in indefinite survival (>100 days) of cardiac allografts in most recipients.
- Recipients showed donor-specific tolerance, accepting BALB/c skin grafts but rejecting third-party C57BL/10 skin grafts.
Conclusions:
- CTLA4-Ig effectively induces long-term survival of vascularized cardiac allografts.
- CTLA4-Ig treatment leads to donor-specific transplantation tolerance in adult mice.
- This study demonstrates the potential of CTLA4-Ig as an immunosuppressive agent for preventing allograft rejection.